Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Tennessee for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Tennessee only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Tennessee (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Bertrand Anz (NPI 1205996014)

Field	Value
Entity Type	Individual
Organization	Bertrand Anz
Address	605 Glenwood Drive
City	Chattanooga
State	TN
ZIP	37404
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	December 11, 2006

Payer Source	Total Paid
Medicare	$2.4M
Medicaid	$0

Key Findings

This provider’s payment activity is effectively single‑payer: total Medicare revenue is $2.4M while Medicaid is none (no Medicaid billing on file), so virtually all reported public‑payer volume and revenue comes from Medicare and the practice has no Medicaid footprint to diversify payer mix. This concentration means the provider’s public reimbursement exposure is tied almost entirely to Medicare policy and beneficiary mix.

Revenue is highly concentrated in a small set of specialty drug administrations: the precomputed top‑3 Medicare codes account for 66.8% of total Medicare revenue, driven by J9271 (32.9%), J9144 (22.5%) and J9173 (11.4%). Those three codes alone explain the majority of the $2.4M Medicare revenue, indicating dependence on a few high‑value infusible biologics.

The code mix and descriptions point to an infusion‑centric hematology/oncology operation: high revenue and claim counts for J9271 (Injection, pembrolizumab, 17.4K claims, $748.2K revenue), J9144 (daratumumab, 13.9K claims, $512.8K revenue) and J9173 (durvalumab, 4.2K claims, $260.4K revenue) alongside chemotherapy administration codes 96413 and add‑on 96417 indicate routine systemic therapy delivery. Supportive agents and ancillary services — J2506 (pegfilgrastim), J0897 (denosumab), J1439 (ferric carboxymaltose) and lab codes 85025/80053 — further signal on‑site infusion and follow‑up services typical of an oncology infusion center.

Competitive standing is mixed across codes: for the top drug J9271 the provider ranks #529 of 1841 (71th percentile) reflecting typical national volume, while J9144 ranks #107 of 615 (82th percentile) showing above‑typical share for that drug; J9173 sits at #25 of 53 (52th percentile) which is modest on the national scale. At the same time, several administration and supportive‑care codes show notably above‑typical volumes — for example J2506 ranks #38 of 586 (93th percentile) and 96413 ranks #270 of 7514 (96th percentile) — indicating the practice is comparatively active in chemotherapy delivery and supportive therapy relative to peers.

Outpatient evaluation and management intensity is a distinctive feature: 99215 accounts for $116.8K of Medicare revenue over 927 claims and the provider ranks #337 of 145531 (100th percentile; labeled an extreme outlier), which suggests a high rate of complex, time‑intensive office visits beyond typical oncology E/M patterns. Other office visit codes such as 99214 and 99213 are present at more typical volumes, but the 99215 outlier signals a clinically complex outpatient panel or documentation/billing profile concentrated at the highest E/M level.

The provider also shows participation in newer oncology payment structures: M0010 (EOM monthly enhanced oncology services) appears with 283 claims and $19.5K revenue and ranks #26 of 544 (95th percentile), suggesting engagement with enhanced oncology services/payments and likely delivery of monthly care management components billed through the Enhanced Oncology Model. This supports the interpretation that the practice provides structured, recurring oncology care beyond episodic infusions.

This entity has an established billing history: NPI was enumerated on 2006-12-11 (~20 years ago), which aligns with a long tenure in the market and accumulation of experience in oncology service delivery. Combined with a $2.4M lifetime Medicare revenue base, the data portray a mid‑scale, established hematology/oncology practice with sustained Medicare activity.

From a strategic and operational perspective the financial picture shows concentration risk: with 66.8% of Medicare revenue tied to three immunotherapy/antibody codes (J9271, J9144, J9173) and no Medicaid revenue to supplement payer mix, the provider’s Medicare margins and volume are sensitive to changes in reimbursement, utilization, or formulary access for those specific agents. Analysts should flag the practice’s dependence on infusible biologics and its strong 99215 footprint when assessing future reimbursement or network negotiations.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

90 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	17,400	$40	$748.2K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	13,860	$40	$512.8K
J9173	Injection, durvalumab, 10 mg	4,200	$60	$260.4K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	930	$130	$116.8K
J0897	Injection, denosumab, 1 mg	4,200	$20	$75.6K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	960	$70	$69.1K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	700	$90	$63.2K
J1439	Injection, ferric carboxymaltose, 1 mg	60,750	$1	$60.8K
J1454	Injection, fosnetupitant 235 mg and palonosetron 0.25 mg	170	$350	$59K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	500	$90	$43.3K

Showing 1–10 of 90

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 90 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Tennessee Distribution

Bertrand Anz — 7 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Tennessee

Full comparison — all codes billed, vs. state median

90 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	25	50	17,400	$40	$776.1K
J9144	8	20	10,080	$40	$466.3K
J9173	2	10	3,720	$60	$211.7K
J0897	88	240	2,940	$20	$85K
J0881	40	70	19,050	$1	$54.4K
J2506	5	40	430	$80	$46.7K
J1439	24	90	34,130	$1	$38.6K
J1454	2	70	70	$340	$25.6K
J9217	54	110	130	$130	$22K
96413	9	240	150	$90	$18.9K

Showing 1–10 of 90

Related Providers

Other providers that share a Tax Identification Number (TIN) with Bertrand Anz, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Tennessee Oncology PLLC	TN	Hematology & Oncology Physician	$0	$8.5M
James Gray	TN	Radiation Oncology Physician	$4.9M	$0
Mark Womack	TN	Hematology & Oncology Physician	$2.4M	$0
Dana Thompson	TN	Medical Oncology Physician	$2.2M	$0
Kent Shih	TN	Hematology & Oncology Physician	$2.2M	$0
Joshua Mondschein	TN	Radiation Oncology Physician	$2.1M	$0
Derek Holland	TN	Hematology & Oncology Physician	$2M	$0
Josiah Magnusson	FL	Nuclear Medicine Physician	$1.8M	$0
William Donnellan	TN	Hematology & Oncology Physician	$1.7M	$0
Clint Kingsley	AL	Hematology & Oncology Physician	$1.6M	$22K

Nearby Providers

Other providers in the same ZIP code as Bertrand Anz, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Parkridge Medical Center, Inc.	TN	General Acute Care Hospital	$0	$26.8M
County Of Hamilton	TN	Land Ambulance	$3.2M	$10.4M
Orange Grove Center, Inc.	TN	Developmentally Disabled Services Day Training Agency	$0	$7.8M
Memorial Health Care System Inc.	TN	General Acute Care Hospital	$0	$4.1M
Erlanger Behavioral Health, LLC	TN	Psychiatric Hospital	$0	$2.2M
Gregory Sutton	TN	Hematology & Oncology Physician	$1.6M	$0
Edward Arrowsmith	TN	Hematology & Oncology Physician	$1.4M	$0
Benjamin Nadeau	TN	Hematology & Oncology Physician	$1.3M	$0
Doloris Hawk	TN	Family Nurse Practitioner	$1.1M	$0
Davey Daniel	TN	Hematology & Oncology Physician	$870.3K	$0

Bertrand Anz — Billing Profile & Reimbursement Data

Sign up for Bertrand Anz — Billing Profile & Reimbursement Data policy alerts

Bertrand Anz — Billing Profile & Reimbursement Data

Sign up for Bertrand Anz — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References